证券代码：688151 证券简称：华强科技 公告编号：2023-017 湖北华强科技股份有限公司 关于参加 2023 年湖北辖区上市公司投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 活动主题：2023 年湖北辖区上市公司投资者网上集体接待日活动 召开时间：2023 年 05 月 25 日(星期四) 14:30-16:35 召开地点：全景路演（http://rs.p5w.net/）网络平台 召开方式：网络文字互动 为进一步加强与广大投资者的互动交流，根据湖北省上市公司协会《关于举 办 2023 年湖北辖区上市公司投资者网上集体接待日活动的通知》，湖北华强科 技股份有限公司（以下简称"公司"）将于 2023 年 5 月 25 日(星期四)14:30-16:35 参加由湖北监管局联合湖北省上市公司协会、深圳市全景网络有限公司举办的 2023 年湖北辖区上市公司投资者网上集体接待日活动，公司将通过网络文字互 动方式与广大投资者沟通交流。现将有关事项公告如下： 一、 活动类型 本次 ...

2023 年第一季度报告 证券代码：688151 证券简称：华强科技 湖北华强科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 主要财务数据 (一)主要会计数据和财务指标 | | | 单位：元 币种：人民币 | | --- | --- | --- | | 项目 | 本报告期 | 本报告期比上年 同期增减变动幅 | | | | 度(%) | | 营业收入 | 191,850,331.44 | -15.61 | | 归属于上市公司股东的净利润 | 17,123,244.96 | -77.25 | | 归属于上市公司股东的扣除非经常 | 7,658,581.64 | -84.31 | | 性损益的净利润 | | | | 经营活动产生的现金流量净额 | -81,949,557.53 | -21.88 | | 基本每股收益（元/股） | 0.05 | -77.27 | | 稀释每股收益（元/股） | 0.05 | -77.27 | 1 / 11 2023 年第一季度报告 | 加权平均净 ...

Financial Performance - The total distributable profit as of December 31, 2022, was RMB 258,899,381.89, with the parent company's distributable profit at RMB 238,983,608.21[5]. - The proposed cash dividend is RMB 0.757 per share (including tax), amounting to a total of RMB 26,078,650.00 based on a total share capital of 344,500,000 shares[5]. - The net profit attributable to shareholders for the year was RMB 72,433,635.82, with a cash dividend payout ratio of 36.00%[5]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2022 was ¥608,880,588.78, a decrease of 52.25% compared to ¥1,275,242,616.54 in 2021[21]. - The net profit attributable to shareholders for 2022 was ¥72,433,635.82, down 77.38% from ¥320,221,815.39 in 2021[24]. - The net profit after deducting non-recurring gains and losses was ¥8,601,873.76, a decline of 96.85% from ¥272,715,928.60 in 2021[21]. - The cash flow from operating activities showed a net outflow of ¥181,302,862.18, a decrease of 138.38% compared to a net inflow of ¥472,426,883.36 in 2021[24]. - The company's total assets at the end of 2022 were ¥5,166,369,693.67, down 2.37% from ¥5,291,914,893.37 at the end of 2021[22]. - The net assets attributable to shareholders at the end of 2022 were ¥4,192,619,022.01, a slight decrease of 0.97% from ¥4,233,697,874.52 at the end of 2021[22]. - Basic earnings per share for 2022 were ¥0.21, down 83.06% from ¥1.24 in 2021[23]. - The company's main business gross margin was 16.61%, a decrease of 26.15 percentage points year-on-year, indicating significant volatility in profitability[86]. - The net cash flow from operating activities was negative CNY 181.30 million, a decline of 138.38% year-on-year, primarily due to delayed sales receipts from military and major customers[82]. Operational Highlights - The company has detailed various operational risks and corresponding mitigation measures in the report[4]. - The audit report issued by Da Xin Accounting Firm was a standard unqualified opinion[5]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company emphasizes that forward-looking statements in the report do not constitute substantive commitments to investors[7]. - The company experienced a significant decline in sales due to delays in military equipment orders and a drop in demand for vaccine-related products[24]. - The company maintained a 100% contract fulfillment rate for military products, demonstrating strong operational performance[33]. - The company successfully delivered 6 units of a newly developed collective protection system, marking a significant milestone in project development[35]. - Medical device shipments included over 100 million medical masks and 560,000 protective suits, meeting annual targets[34]. - The company completed all 45 reform measures under the state-owned enterprise reform initiative, enhancing operational vitality[34]. - The company’s military and civil products maintained a 100% first-time pass rate during inspections, ensuring quality assurance[33]. Research and Development - The R&D expenditure as a percentage of operating revenue increased by 6.17 percentage points to 10.79% in 2022[23]. - R&D investment reached a historical high as a percentage of revenue, reflecting the company's commitment to technological innovation[35]. - The company has developed 15 core technologies, including integrated design technology for respiratory devices and broad-spectrum filtering materials for military applications[55]. - The company has been recognized as a national high-tech enterprise and has received multiple awards for technological advancements in both military and civilian sectors[55]. - Total R&D investment reached approximately ¥65.71 million, an increase of 11.52% compared to the previous year, with R&D expenses accounting for 10.79% of operating revenue, up from 4.62%[58]. - The number of R&D personnel increased to 139, representing 19.58% of the total workforce, compared to 127 and 17.96% in the previous year[64]. - The company is committed to continuous R&D investment in new technologies and products to maintain its competitive advantage in the special protective equipment market[74]. Market and Industry Trends - The special protection industry is experiencing rapid growth due to increasing defense budgets and the rising demand for advanced military equipment, as outlined in the national "14th Five-Year Plan"[45]. - The global pharmaceutical market is expected to exceed $150 billion by 2025, driven by population growth and aging[47]. - The overall pharmaceutical packaging market in China has a low concentration, with many small enterprises producing simple products, indicating growth opportunities for larger players[47]. - The aging population in China presents significant growth opportunities for the pharmaceutical and pharmaceutical packaging industries[126]. - The implementation of volume-based procurement is driving companies to enhance product quality and develop new products, promoting economies of scale in the pharmaceutical packaging sector[127]. - The competitive landscape in the military supply industry is intensifying, with lower market entry barriers allowing more companies to participate[125]. Corporate Governance and Compliance - The board of directors has approved the profit distribution plan, pending approval at the annual shareholders' meeting[5]. - The company has established a mechanism for independent directors to provide opinions on the profit distribution plan, ensuring transparency and accountability[186]. - The company has established a robust internal control system to enhance risk prevention capabilities and operational standards[141]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate reporting to shareholders through various communication channels[141]. - The company has a structured performance assessment management system for determining senior management remuneration[161]. - The company has established a modern corporate governance structure, including various specialized committees to enhance decision-making efficiency[194]. Environmental and Social Responsibility - The company invested 1.9378 million yuan in environmental protection during the reporting period[195]. - The company consumed 30.2923 million kWh of electricity and 653,200 tons of water in 2022[199]. - The company disposed of 1,155 tons of general industrial solid waste and 50.26 tons of hazardous waste in 2022[200]. - The company reported emissions of 0.0314 tons of sulfur dioxide and 1.43 tons of nitrogen oxides in 2022, all pollutants met discharge standards[200]. - The company emphasizes the integration of ESG into its business strategy to enhance corporate governance and social responsibility[193]. Future Outlook - The company provided a positive outlook for 2023, projecting a revenue growth of 25% and aiming to reach 1.875 billion[150]. - New product launches are expected to contribute an additional 300 million in revenue in the upcoming year[150]. - Market expansion plans include entering three new international markets by the end of 2023, targeting a 10% market share in each[150]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 500 million allocated for potential deals[150].

证券代码：688151 证券简称：华强科技 公告编号：2023-014 湖北华强科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 04 月 28 日(星期五) 上午 10:00-11:30 （一） 会议召开时间：2023 年 04 月 28 日 上午 10:00-11:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频录播和网络互动 投资者可于 2023 年 04 月 21 日(星期五)至 2023 年 04 月 27 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （office@hqtc.com）进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 湖北华强科技股份有限公司（以下简称"公司"）已于 202 ...

编号：2022-003 证券代码 688151 证券简称：华强科技 湖北华强科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------|---------------------------------------------|---------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关 | □媒体采访 | ☑ 业绩说明会 | | 系活动类 | □新闻发布会 □路演活动 | | | 别 | | □现场参观 □其他（电话沟通） | | 参与单位 | | 通过上海证券交易所上证路演中心和上海证券报·中国证券网参 | | 名称 | 与公司 2021 年度暨 | 2022 年一季度业绩说明会的投资者 | | 时间 | 2022 年 5 月 24 日 | 下午 15:00-16:30 | | 地点 | | 上海证券交易所上证路演中心、上海证券报·中国证券网 | | | 董事长 党委书记：孙光幸先生 | | | | 董事 总经理：高新发先生 | | | 上市公司 | ...

编号：2022-004 证券代码 688151 证券简称：华强科技 湖北华强科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |---------------|-------------------------------|--------------------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关 | □媒体采访 | ☑ 业绩说明会 | | 系活动类 | □新闻发布会 □路演活动 | | | 别 | □现场参观 | □其他（电话沟通） | | | | 通过全景网"投资者关系互动平台"参与公司" 2022 年湖北辖区 | | 参与单位 名称 | 上市公司投资者集体接待日暨 | 2021 年度业绩说明会"的广大投资 | | | 者 | | | 时间 | 2022 年 6 月 16 日 | 13:00-16:00 | | | 全景网"投资者关系互动平台"（ | http://ir.p5w.net ...

2022 年第三季度报告 证券代码：688151 证券简称：华强科技 湖北华强科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | --- | |--------|-------------------------------------------|----------------|---------------------------------------|-----------------|---------------------------------- ...

公司代码：688151 公司简称：华强科技 2022 年半年度报告 湖北华强科技股份有限公司 2022 年半年度报告 1 / 169 2022 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、重大风险提示 公司已在本报告中描述公司面临的风险，敬请查阅本报告"第三节 管理层讨论与分析"之 "五、风险因素"相关内容，请投资者予以关注。 三、公司全体董事出席董事会会议。 四、本半年度报告未经审计。 五、公司负责人孙光幸、主管会计工作负责人朱经平及会计机构负责人（会计主管人员）王德彬 声明：保证半年度报告中财务报告的真实、准确、完整。 六、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺， 请投资者注意投资风险。 九、是否存在被控股股东及其关联方非经营性占用资金情况 否 十、是否存在违 ...

2022 年第一季度报告 单位：元 币种：人民币 证券代码：688151 证券简称：华强科技 湖北华强科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|-----------------|------------------------------------------| | 项目 | 本报告期 | 本报告期比上年 \n同期增减变动幅 \n度 (%) | | 营业收入 | 227,34 ...

Financial Performance - The company reported a total distributable profit of RMB 291,352,150.30 as of December 31, 2021[7]. - A cash dividend of RMB 3.35 per 10 shares (including tax) is proposed, totaling RMB 115,407,500.00 (including tax) based on a total share capital of 344,500,000 shares[7]. - The cash dividend represents 36.04% of the net profit attributable to the parent company[7]. - In 2021, the company's operating income increased by 52.70% year-on-year, reaching ¥1,275,242,616.54, primarily due to increased sales of vaccine-related products and collective protection products[28]. - The net profit attributable to shareholders of the listed company rose by 81.74% year-on-year to ¥320,221,815.39, driven by higher sales volumes and improved operational efficiency[28]. - The net cash flow from operating activities increased by 250.88% year-on-year, amounting to ¥472,426,883.36, attributed to favorable sales collection from military and major clients[28]. - The company's total assets grew by 128.98% year-on-year, reaching ¥5,291,914,893.37, while net assets attributable to shareholders increased by 265.58% to ¥4,233,697,874.52[28]. - Basic earnings per share rose by 69.86% to ¥1.24, with diluted earnings per share also at ¥1.24, reflecting strong profit growth[28]. - The company achieved a total operating revenue of RMB 1,275.24 million in 2021, representing a year-on-year growth of 52.70%[39]. - The net profit attributable to the parent company was RMB 320.22 million, an increase of 81.74% compared to the previous year[39]. - The net profit attributable to the parent company after deducting non-recurring gains and losses reached RMB 272.72 million, showing a significant growth of 311.52% year-on-year[39]. Corporate Governance - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated decision-making procedures for external guarantees[11]. - The company has not reported any special arrangements for corporate governance[11]. - The company has provided a standard unqualified audit report from Da Xin Accounting Firm[6]. - The board of directors and supervisory board members have confirmed the authenticity and completeness of the annual report[4]. - The company has established a robust corporate governance structure, ensuring clear responsibilities and effective decision-making processes among its board and management[152]. - The company has implemented comprehensive internal management and control systems to protect the rights of shareholders and ensure compliance with regulations[152]. - The company maintains strict independence from its controlling shareholders in operations, personnel, assets, and finances, ensuring self-sustaining operational capabilities[152]. - The company has conducted multiple shareholder and board meetings, ensuring transparency and adherence to legal and regulatory requirements in decision-making processes[152]. Research and Development - The company's R&D investment as a percentage of operating income was 4.62%, slightly down from 4.74% in the previous year[28]. - The company has achieved a 48.72% year-on-year increase in R&D expenses, totaling approximately CNY 58.92 million, to maintain technological advantages and expand research directions[71]. - The company has developed 14 core technologies related to its main business, including advanced materials and integrated design technologies for protective equipment[65]. - The company is recognized as a national high-tech enterprise and has received multiple awards for technological progress, including first, second, and third prizes from military science and technology awards[65]. - The company is investing heavily in R&D for new technologies, with a budget allocation of 209,500 for the technology center[166]. - The company is committed to building a robust innovation network to enhance manufacturing capabilities and support the development of new protective materials and technologies[143]. Market and Product Development - The company plans to continue expanding its product offerings in pharmaceutical packaging and collective protection sectors to sustain growth[28]. - The company has established itself as a core supplier of pharmaceutical packaging, particularly for vaccine-related products, ensuring a steady supply during the COVID-19 pandemic[44]. - The company is involved in advanced research and development for next-generation military equipment, enhancing its technological capabilities in the special protective equipment sector[53]. - The company plans to accelerate the development of new products in the medical packaging sector, including pre-filled components and protective gear related to COVID-19[143]. - The company is focusing on expanding its production capacity and enhancing its operational efficiency as part of its strategic planning[184]. - The company is actively pursuing major technological innovations to achieve breakthroughs in key areas, particularly in special protection and pharmaceutical packaging sectors[147]. Risks and Challenges - The company has outlined various operational risks and corresponding countermeasures in the report[5]. - The company faces risks related to high customer concentration, which could significantly impact its operational performance if it fails to maintain its competitive edge[91]. - The company has a significant reliance on foreign suppliers for raw materials, which poses risks related to international trade conditions and political relations[91]. - The company has not experienced actual bad debts from military accounts receivable, but the collection period may be prolonged due to military payment cycles[92]. Employee and Management - The company has 127 R&D personnel, accounting for 17.96% of the total workforce, with an average salary of 26.50 thousand CNY[81]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 4.4369 million RMB[181]. - The company has a structured performance assessment management method for determining the remuneration of senior management, overseen by the board's remuneration and assessment committee[181]. - The company has established a long-term incentive mechanism to bind employees closely with the company's performance and risk sharing[198]. - The company is focusing on training programs aligned with the "14th Five-Year Plan" to enhance employee capabilities and support sustainable development[199]. Strategic Initiatives - The company plans to enhance talent development through three major initiatives: technology leadership, management leadership, and skills leadership, with a focus on competitive compensation for core talents[146]. - The company is committed to expanding its market presence by improving after-sales service and ensuring timely delivery of quality products, targeting both military and civilian markets[147]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[171]. - The company has introduced several new products that are expected to drive sales in the upcoming quarters[166]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of the next fiscal year[174].